about
Genome-wide association study of lifetime cannabis use based on a large meta-analytic sample of 32 330 subjects from the International Cannabis ConsortiumUnderestimated effect sizes in GWAS: fundamental limitations of single SNP analysis for dichotomous phenotypes.Assumptions and properties of limiting pathway models for analysis of epistasis in complex traitsGenetic liability for schizophrenia predicts risk of immune disorders.What Cure Models Can Teach us About Genome-Wide Survival Analysis.A guide on gene prioritization in studies of psychiatric disorders.Majority of human traits do not show evidence for sex-specific genetic and environmental effectsGenome-wide association analysis of insomnia complaints identifies risk genes and genetic overlap with psychiatric and metabolic traits.Genome-wide association meta-analysis of 78,308 individuals identifies new loci and genes influencing human intelligence.A systems medicine research approach for studying alcohol addiction.Happiness, health, and mortality.Item-level analyses reveal genetic heterogeneity in neuroticism.Genome-wide association meta-analysis in 269,867 individuals identifies new genetic and functional links to intelligenceConditional and interaction gene-set analysis reveals novel functional pathways for blood pressureGWAS of lifetime cannabis use reveals new risk loci, genetic overlap with psychiatric traits, and a causal influence of schizophreniaAuthor Correction: Majority of human traits do not show evidence for sex-specific genetic and environmental effectsMeta-analysis of genome-wide association studies for neuroticism in 449,484 individuals identifies novel genetic loci and pathwaysAuthor Correction: Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer's disease riskGenome-wide analysis of insomnia in 1,331,010 individuals identifies new risk loci and functional pathwaysAuthor Correction: GWAS of lifetime cannabis use reveals new risk loci, genetic overlap with psychiatric traits, and a causal effect of schizophrenia liability
P50
Q28274406-8446A0A2-E55D-44C8-BEF4-908221836FAAQ34091168-748E8A6F-DA9E-4C1B-B32A-48C0BEB409D1Q34918790-3414ECCA-4681-4565-A468-D098FDBA1F2DQ38255331-B4ACB793-03BD-46BC-A7BF-FC42E19187B4Q38374378-E7521CA6-B2AF-4013-A383-68004E12B2F2Q38558394-D3F1B01B-7AF5-493F-9EA6-DA4A9A4F70CCQ38640524-BA89E561-1451-4696-92F4-A6EE74F43C01Q40163637-4B3D7EED-F81A-435B-9EE6-32EB3A948DC3Q40191170-44D00809-3327-4354-8E64-E244A3F0399CQ45260924-0DD04CA8-EAFC-4862-975E-80FCEE09AD79Q50197469-2F306740-D1F9-4906-AD66-12335EAF8557Q52368856-E3A4BE99-9CF7-40E0-BF19-7D3E22253697Q56967082-0188EF2B-5EFA-43BB-B364-1A4A960403F4Q57700143-2304F633-541F-419A-B5DE-459630A24A43Q57700145-6196BBF7-E839-4848-87D5-F724F7918310Q60300497-344C334F-5B55-46B0-82D5-1570DAD5C937Q89243403-137DF65D-0E59-45B6-8C9C-EB84D5CFF2D4Q89583879-CF9409CD-52BC-43B2-BC9F-960FCCF74B7CQ91908180-C0E0FE6D-CAD1-4133-BD7E-574B9E287741Q92548462-D1E3D48B-4CBC-4DEA-B26E-BDBBD549C907
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Sven Stringer
@ast
Sven Stringer
@en
Sven Stringer
@es
Sven Stringer
@nl
Sven Stringer
@sl
type
label
Sven Stringer
@ast
Sven Stringer
@en
Sven Stringer
@es
Sven Stringer
@nl
Sven Stringer
@sl
altLabel
S. Stringer
@nl
Stringer S
@en
prefLabel
Sven Stringer
@ast
Sven Stringer
@en
Sven Stringer
@es
Sven Stringer
@nl
Sven Stringer
@sl
P106
P21
P2798
P31
P496
0000-0003-3115-8532